SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
SEC Accession No. 0001104659-18-023059
Filing Date
2018-04-09
Accepted
2018-04-09 16:12:39
Documents
6

Document Format Files

Seq Description Document Type Size
1 S-3/A a18-9382_1s3a.htm S-3/A 584873
2 EX-5.1 a18-9382_1ex5d1.htm EX-5.1 39226
3 EX-23.1 a18-9382_1ex23d1.htm EX-23.1 4380
4 EX-23.2 a18-9382_1ex23d2.htm EX-23.2 4765
5 GRAPHIC g93821kgi001.jpg GRAPHIC 2457
6 GRAPHIC g93821bci001.jpg GRAPHIC 4006
  Complete submission text file 0001104659-18-023059.txt   643506
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: S-3/A | Act: 33 | File No.: 333-223739 | Film No.: 18745719
SIC: 2834 Pharmaceutical Preparations